TNGX / Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates

We are circling back on clinical stage developmental concern Tango Therapeutics, Inc. for the first time since November 2022. The company recently rai more_horizontal

The upside in Tango's (TNGX) shares can be attributed to the company's progress with its pipeline candidates. A recent acquisition offer for a biotech more_horizontal

Tango Therapeutics is a clinical-stage biotech. The company has five programs in its pipeline that are focused on fighting various cancers. more_horizontal

Tango Therapeutics, Inc. (TNGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit more_horizontal

Tango said it has $310.7 million in cash, enough to fund operations into 2026. The company has several early-stage trials. more_horizontal

Tango Therapeutics just beefed up its cash reserves with a private stock sale. Tango's pipeline has a few early-stage programs that may become promisi more_horizontal

Tango increased revenue and reduced net loss in the quarter. The biotech company has several cancer therapies in early-stage trials. more_horizontal

Tango Therapeutics (NASDAQ: TNGX ) stock is soaring higher on Wednesday after getting a couple of updates from analysts covering the shares. Starting more_horizontal